证券代码：688180 证券简称：君实生物 公告编号：临 2025-065 上海君实生物医药科技股份有限公司 关于控股股东、实际控制人之一兼董事长 增持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 上海君实生物医药科技股份有限公司（以下简称"公司"）控股股东、 实际控制人之一兼董事长熊俊先生拟自 2025 年 4 月 12 日起 12 个月内，通过上 海证券交易所交易系统与香港联合交易所有限公司允许的方式（包括但不限于集 中竞价和大宗交易等方式）增持公司 A 股股份及 H 股股份，合计增持金额不低 于人民币 1 亿元，其中 A 股增持金额不低于人民币 5,000 万元。 截至本公告披露日，熊俊先生通过上海证券交易所系统以集中竞价方式 累计增持公司 A 股股份 100,000 股，约占公司总股本的 0.01%，累计成交总额为 人民币 383.84 万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增 持计划，在增持计划实施期间内择机增持公司股份。 本次增持计划可能存在因资本市场 ...

格隆汇11月10日丨君实生物(688180.SH)公布，截至本公告披露日，实际控制人之一兼董事长熊俊先生 通过上海证券交易所系统以集中竞价方式累计增持公司A股股份10万股，约占公司总股本的0.01%，累 计成交总额为人民币383.84 万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增持计划，在 增持计划实施期间内择机增持公司股份。 ...

Core Points - The actual controller and chairman of Junshi Biosciences, Mr. Xiong Jun, has cumulatively increased his holdings in the company's A-shares by 100,000 shares, representing approximately 0.01% of the total share capital [1] - The total transaction amount for this increase in holdings is RMB 3.8384 million [1] - The share buyback plan is not yet completed, and Mr. Xiong will continue to increase his holdings in the company during the implementation period of the buyback plan [1]

Market Overview - The metal new materials sector experienced a decline of 0.98% on November 10, with Yunlu Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] Stock Performance - Jiangnan New Materials (603124) saw a significant increase of 8.15%, closing at 89.66 with a trading volume of 64,900 shares and a transaction value of 575 million [1] - Sry New Materials (688102) rose by 5.15%, closing at 20.40 with a trading volume of 300,800 shares and a transaction value of 629 million [1] - In contrast, Yunlu Co., Ltd. (688180) fell by 8.08%, closing at 115.25 with a trading volume of 17,500 shares and a transaction value of 207 million [2] Capital Flow - The metal new materials sector saw a net outflow of 844 million from institutional investors, while retail investors contributed a net inflow of 743 million [2] - The overall capital flow indicates that retail investors are actively buying into the sector despite the institutional sell-off [2] Individual Stock Capital Flow - Jiangnan New Materials had a net inflow of 68.28 million from institutional investors, while retail investors had a net outflow of 55.55 million [3] - Longmag Technology (300835) experienced a net inflow of 12.87 million from institutional investors, with retail investors also showing a net outflow of 19.28 million [3] - The data suggests a mixed sentiment among different investor types, with institutional investors pulling back while retail investors remain engaged [3]

Core Viewpoint - The A-share market is experiencing a rebound with strong performance in sectors like consumer goods, food and beverage, and oil, while sectors such as communication and electronics are under pressure. The "20CM New Species" Sci-Tech Innovation Drug ETF Huatai (589120) has seen a significant inflow of funds, accumulating over 190 million yuan in nine consecutive days, with a total scale exceeding 500 million yuan [1][3]. Group 1: Market Performance - The A-share market is showing a mixed trend, with certain sectors like consumer goods and food and beverage performing strongly, while others like communication and electronics are facing challenges [1]. - The "20CM New Species" Sci-Tech Innovation Drug ETF Huatai (589120) has risen over 1% amid this market fluctuation, indicating investor interest in innovative drug sectors [1]. Group 2: Fund Inflows and Performance - The Sci-Tech Innovation Drug ETF Huatai (589120) has attracted over 190 million yuan in funds over the past nine days, reflecting strong investor confidence in the innovative drug sector [1]. - The ETF's latest scale has surpassed 500 million yuan, showcasing its growing popularity among investors [1]. Group 3: Company-Specific Developments - BeiGene reported a 41% year-on-year increase in third-quarter revenue, reaching 1.41 billion USD, primarily driven by strong sales of its drug, Zebrutinib [3]. - Several component stocks of the ETF, such as Teva Biopharma and Zai Lab, have shown positive performance, with Teva Biopharma rising over 4% [3][4]. Group 4: Policy and Market Dynamics - The National Medical Insurance Administration is conducting negotiations for the medical insurance drug catalog, with 120 companies participating, indicating a significant policy shift aimed at enhancing drug accessibility [5][6]. - The introduction of a dual catalog negotiation system allows pharmaceutical companies more strategic options, potentially leading to better market access for innovative drugs [6][7]. Group 5: Future Outlook - The innovative drug sector is expected to continue thriving, supported by favorable policies and increasing international collaboration, with projections indicating substantial market growth by 2030 [8]. - The focus on innovative drugs, particularly in the context of the upcoming medical insurance negotiations, is likely to enhance the market landscape for these products [8].

Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price and significant trading activity, indicating high levels of financing and short selling [1][2] Group 2 - On November 7, Junshi Biosciences' stock fell by 1.92%, with a trading volume of 292 million yuan. The financing buy-in amount was 2.023 million yuan, while the financing repayment was 26.51 million yuan, resulting in a net financing buy of -627.79 thousand yuan [1] - As of November 7, the total financing and securities lending balance for Junshi Biosciences was 1.402 billion yuan, with the financing balance at 1.389 billion yuan, accounting for 4.80% of the circulating market value, which is above the 90th percentile level over the past year [1] - On the same day, Junshi Biosciences repaid 1,490 shares in securities lending and sold 2,000 shares, with a selling amount of 75.6 thousand yuan. The remaining securities lending volume was 32.85 thousand shares, with a balance of 12.4132 million yuan, also above the 90th percentile level over the past year [1] Group 3 - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs. The main revenue sources are 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [2] - As of September 30, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2] - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [2] - As of September 30, 2025, the top ten circulating shareholders included E Fund's SSE STAR 50 ETF and Huaxia's SSE STAR 50 Component ETF, with both funds reducing their holdings compared to the previous period [2]

88888888 ...

中国经济网北京11月7日讯 君实生物(688180.SH)今日收报37.79元，跌幅1.92%。该股目前处于破发 状态。 经计算，君实生物两次募集资金合计86.12亿元。 2016年至2024年，君实生物归属于上市公司股东的净利润分别为-1.35亿元、-3.17亿元、-7.23亿 元、-7.47亿元、-16.69亿元、-7.21亿元、-23.88亿元、-22.83亿元、-12.81亿元；归属于上市公司股东的 扣除非经常性损益的净利润分别为-1.60亿元、-3.00亿元、-7.06亿元、-7.76亿元、-17.09亿元、-8.84亿 元、-24.50亿元、-22.98亿元、-12.90亿元。 2025年前三季度，公司实现营业收入18.06亿元，同比增长42.06%；归属于上市公司股东的净利润 为-5.96亿元，上年同期为-9.27亿元；归属于上市公司股东的扣非净利润为-6.7亿元，上年同期为-9.4亿 元；经营活动产生的现金流量净额为-3.43亿元，上年同期为-11.13亿元。 （责任编辑：关婧） 君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿 元，较原计划多1 ...

来源：新浪基金∞工作室 11月7日，君实生物跌1.92%，截至发稿，报37.79元/股，成交2.92亿元，换手率1.00%，总市值387.99亿 元。君实生物股价已经连续5天下跌，区间累计跌幅6.39%。 截至发稿，李会忠累计任职时间11年116天，现任基金资产总规模2.33亿元，任职期间最佳基金回报 70.73%， 任职期间最差基金回报-39.92%。 王毕功累计任职时间361天，现任基金资产总规模9416.11万元，任职期间最佳基金回报1.11%， 任职期 间最差基金回报0.73%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 从基金十大重仓股角度 数据显示，格林基金旗下1只基金重仓君实生物。格林鑫悦一年持有期混合A（011775）三季度持有股 数3.3万股，占基金净值比例为1.45%，位居第九大重仓股。根据测算，今日浮亏损失约2.44万元。连续 5天下跌期间浮亏损失8.51万元。 格林鑫悦一年持有期混合A（011775）成立日期2021年6月9日，最新规模573 ...

Investment Rating - The report indicates a positive outlook for the non-ferrous metals industry, with a focus on ESG performance management among central enterprises [3][4]. Core Insights - The report evaluates 18 central enterprises in the non-ferrous metals sector based on an established ESG rating system, highlighting that 11 companies scored over 100 points, reflecting a systematic approach to ESG management [4][12]. - Environmental management is prioritized, with comprehensive disclosure on pollution control, waste management, and energy utilization, although there is room for improvement in areas like green mining and circular economy indicators [4][24]. - The report emphasizes the importance of climate-related governance, with many companies actively addressing climate change and setting reduction targets, though mechanisms for information acquisition need enhancement [4][42]. - Social responsibility is a key focus, with all companies covering social indicators, but there is a noted deficiency in disclosures related to technology ethics [4][61]. - Governance structures are generally robust, but there is a need for improvement in due diligence practices, particularly concerning compliance checks of supply chain partners [4][75]. Summary by Sections 1. Overall Scores and ESG Governance - The overall ESG scores for the 18 central enterprises are high, with 61.1% scoring above 100 points, indicating a well-established ESG management framework [12]. 2. Importance Assessment: Need for Third-Party Verification - All companies disclosed financial and impact importance assessments, but only 11% provided third-party verification, indicating a gap in independent validation [16][17]. 3. Environmental: Mature Disclosure, Comprehensive Management - Environmental indicators show high scores, with 67% of companies achieving full marks, reflecting strong environmental protection awareness [24][27]. 4. Climate: Accelerating Disclosure Framework - 67% of companies received full scores for climate-related disclosures, demonstrating a high level of commitment to addressing climate change [42][49]. 5. Social: Commitment to Social and Management Responsibilities - Social responsibility indicators are fully covered by all companies, but technology ethics disclosures are lacking [61][64]. 6. Governance: Well-Structured, Need for Enhanced Due Diligence - Governance structures are generally well-defined, with high coverage of governance mechanisms, but due diligence practices require further development [75][76].